Study Title: Combination MCI Metabolic Syndrome (COMMETS)
Intervention: Semaglutide + Intranasal Insulin
Phase: Phase 2
Participants: 80
Status: Recruiting
This trial targets metabolic dysfunction in MCI patients with metabolic syndrome. The combination approach:
Type 3 diabetes hypothesis links AD to insulin resistance. Metabolic syndrome (obesity, hypertension, dyslipidemia) increases AD risk 2-3x. This combo addresses: